Comparison · prescription peptides
Semaglutide vs tirzepatide
The two biggest names in diabetes and weight-loss medicine are both engineered peptides — but they don’t work quite the same way. Here’s a clear, side-by-side comparison of mechanism, results, side effects and safe access.
The short version
Semaglutide (Ozempic, Wegovy, Rybelsus) activates one gut-hormone receptor: GLP-1. Tirzepatide (Mounjaro, Zepbound) is a dual agonist that activates two — GIP and GLP-1. In head-to-head trials, that second receptor helped tirzepatide deliver greater average weight loss. Both are genuine, approved, prescription-only medicines — and the “right” one for a given person depends on their health, tolerance and access, not a leaderboard.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brand names | Ozempic, Rybelsus (diabetes); Wegovy (weight loss) | Mounjaro (diabetes); Zepbound (weight loss) |
| Mechanism | GLP-1 receptor agonist (single) | GIP + GLP-1 dual agonist |
| Average weight loss* | Substantial; strong trial results | Greater on average in head-to-head data |
| Main side effects | GI: nausea, vomiting, diarrhoea, constipation | GI: nausea, diarrhoea, vomiting, constipation |
| Dosing | Weekly injection; oral form exists (Rybelsus) | Weekly injection |
| Status | Prescription-only, regulator-approved | Prescription-only, regulator-approved |
*Averages from clinical trials; individual results vary widely. Figures here are directional, not a substitute for current prescribing information.
How the mechanisms differ
Both drugs imitate GLP-1, a gut hormone that boosts insulin when blood sugar is high, slows stomach emptying and signals fullness to the brain. Tirzepatide adds a second action on the GIP receptor, another incretin hormone involved in insulin response and fat metabolism. The prevailing theory is that hitting both pathways is what gives tirzepatide its edge on average weight loss — though the science of exactly why is still being worked out.
Which produces more weight loss?
In the head-to-head SURPASS-2 trial (in type-2 diabetes) and broader comparisons, tirzepatide generally produced greater average weight loss than semaglutide. But “greater on average” is not “better for everyone”: some people tolerate one far better than the other, insurance and availability differ, and side-effect burden matters. This is exactly the kind of trade-off a prescriber weighs with you.
Side effects & tolerability
The side-effect profiles are similar — predominantly gastrointestinal (nausea, diarrhoea, vomiting, constipation), usually worst while the dose is being titrated up and easing with time. Both carry specific warnings and contraindications (including certain thyroid-cancer history and pancreatitis risk). That’s why both are prescription-only and require medical monitoring.
Getting either one safely
Both are prescription medicines. The safe, legal route is a licensed clinician — your own doctor or a legitimate, regulated telehealth service — who prescribes the real, pharmacy-dispensed product and monitors you. Steer clear of “research” semaglutide or tirzepatide and unlicensed compounded copies: they’re unregulated, of unknown quality, and legally risky.
Frequently asked questions
Read the full guides
Not medical advice. Chemdu is an educational resource and does not recommend, prescribe or supply any medication. Comparative figures are directional and change as evidence evolves — always consult a licensed clinician and current prescribing information.